ClinicalTrials.gg
TerminatedNCT05144347Updated Jul 11, 2023

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

A Phase 1 interventional study of XL114 in Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL) and Mantle Cell Lymphoma (MCL), sponsored by Exelixis. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-11.

Primary conditionLymphoma, Mantle-CellRegistry: Lymphoma, Non-HodgkinReclassifiedWhy we changed it
Registry
Lymphoma, Non-Hodgkin — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Mantle-Cell
Why
  1. The study's listed conditions name Lymphoma, Mantle-Cell, a narrower term within Lymphoma, Non-Hodgkin.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Exelixis · Phase 1, Interventional, and Treatment

Why this study was terminated
Due to Sponsor reasons.

From the registry’s dates

  • Primary completion was Nov 2022, 4 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
2
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 905 studies in Lymphoma, Mantle-Cell with a site in United States — 81 open to participants now, 149 under way, 7 of them phase 3. Lymphoma, Mantle-Cell · United States.

Enrollment
733rd of 777
2 · median 35
Started
2022
with 14 others
Phase 1
313 of 905
27 open now
Registered
820th of 905
by date

Among the 905 studies in Lymphoma, Mantle-Cell with a site in United States, this one is the 733rd largest by enrollment of the 777 interventional ones that give a count, is one of 15 that started in 2022, is one of 313 in phase 1, and was the 820th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 154 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

81 of the 905 studies in Lymphoma, Mantle-Cell with a site in United States are open now. Recruiting first, the newest first:

76 more — sign in →

All 81 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 905 studies in Lymphoma, Mantle-Cell with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, non-randomized, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical antitumor activity of XL114 administered alone orally to subjects with Non-Hodgkin's Lymphoma (NHL). The objectives of the study also include determining the recommended dose (RD) and/or maximum tolerated dose (MTD) of XL114.

03

Conditions studied

  • Non-Hodgkin's Lymphoma (NHL)
  • Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL)
  • Mantle Cell Lymphoma (MCL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)

Keywords

  • Mucosa-associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT-1)
  • B-cell Malignancies
  • Fatty Acid Binding Protein 5 (FABP-5)
04

In context

Lymphoma, Mantle-Cell Reclassified

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 154 are open to participants now.

This study's enrollment of 2 is below the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.

Browse Lymphoma, Mantle-Cell studies →

Lead sponsor

Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Lymphoma, Mantle-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Dose-Escalation Stage (Cohort A) and Cohort-Expansion Stage (B-E): The subject has received standard life-prolonging therapies or are not qualified to receive such therapies.
  • Dose-Escalation Stage (Cohort A): Subjects with documented diagnosis of B-cell or T-cell Non-Hodgkin's Lymphoma as defined by the World Health Organization (WHO) classification. Note: Refer to exclusion criteria for lymphoma subtypes which are excluded from study participation.
  • Cohort-Expansion Stage Cohort B (ABC-DLBCL subtype): Subjects with histologically documented activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) subtype. Note: De novo or transformed diffuse large B-cell lymphoma (DLBCL) from previously diagnosed indolent lymphoma (eg, follicular lymphoma) is allowed.
  • Cohort-Expansion Stage Cohort C (MCL): Subjects with histologically documented MCL with monoclonal B-cells that show a chromosome translocation t(11;14)(q13;q32) and/or overexpression of cyclin D1.
  • Cohort-Expansion Stage Cohort D (CLL/SLL): Subjects with histologically documented CLL/SLL per the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines.
  • Cohort-Expansion Stage Cohort E, Biomarker Cohort (ABC-DLBCL, MCL, and SLL): Subjects with ABC-DLBCL, MCL, and SLL that fulfill the subject disease characteristics criteria as described for Cohorts B, C, or D.
  • Cohort-Expansion Stage: Subjects with ABC-DLBCL, MCL, and SLL must have by revised criteria for response assessment of lymphoma.
  • Cohort-Expansion Stages: Must have available, which was collected up to 2 years prior to consent for this study. If archival tumor tissue is not available, a fresh tumor biopsy may be obtained (if safe to acquire) up to 60 days prior to first dose.
  • Biomarker Cohort: Subjects must provide a fresh tumor biopsy up to 60 days prior to first dose, at week 2, day 1 (W2D1) after initiation of XL114, and at disease progression. Note: The tumor tissue requirement in the Expansion and Biomarker cohorts doesn't apply for subjects with CLL.
  • Recovery to baseline or ≤ Grade 1 severity ( version 5 [CTCAE v5]) from AEs, unless AEs are clinically nonsignificant or stable.
  • (LVEF) > 50% as determined by echocardiogram (ECHO) or multigated acquisition (MUGA) scan per local standard.
  • Age 18 years or older on the day of consent.
  • Performance Status (ECOG PS) of 0-1
  • Adequate organ and marrow function
  • Sexually active fertile subjects and their partners must agree to highly effective methods of .
  • Female subjects of must not be pregnant at screening.

Exclusion criteria

Exclusion Criteria:

  • Receipt of prior therapies as defined in the protocol
  • The following lymphoma types/manifestations are not eligible for this study: Burkitt's lymphoma (BL), Burkitt-like lymphoma (BLL), lymphoblastic lymphoma/leukemia (LBL), post-transplant lymphoproliferative disease (PTLD), primary mediastinal (thymic) large B-cell lymphoma (PMBL), lymphomas involving the central nervous system (CNS) or meninges
  • History of hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP).
  • History of solid organ or hematopoietic stem cell transplantation.
  • Concomitant anticoagulation with the oral anticoagulants apixaban, betrixaban, rivaroxaban, and dabigatran.
  • Use of a strong inhibitor or inducer of cytochrome P450 3A4 () within 5 half-lives or 4 weeks prior to first dose of study treatment, whichever is shorter.
  • Uncontrolled, significant intercurrent or recent illness
  • Major surgery (eg, GI surgery) within 3 weeks before first dose of study treatment.
  • interval calculated by the Fridericia formula (QTcF) > 470 ms per (ECG).
  • Pregnant or lactating females.
  • Inability to swallow XL114 tablets.
  • Diagnosis of another within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    XL114 Dose-Escalation Cohorts

    Subjects (Cohort A1-An) will accrue in cohorts of 3-12 subjects in a i3+3 design.

    Drug: XL114

  • Experimental
    XL114 Expansion Cohorts

    The recommended dose from the Dose-Escalation stage, will be used in subjects with activated B-cell-like diffuse large B-cell lymphoma \[ABC-DLBCL\] (Cohort B), mantle cell lymphoma \[MCL\] (Cohort C), chronic lymphocytic leukemia \[CLL\]/small lymphocytic lymphoma \[SLL\] (Cohort D). Subjects will also be enrolled in a Biomarker cohort (Cohort E).

    Drug: XL114

Interventions

  • DrugXL114

    Tablets of XL114

07

What researchers measure

Primary outcomes

  1. Dose-Escalation Stage: Recommended Dose (RD) and/or Maximum Tolerated Dose (MTD) for XL114

    To determine the RD and/or MTD of XL114 administered orally in subjects with NHL

    Time frame: 4-6 months

  2. Cohort-Expansion Stage: Objective Response Rate (ORR)

    To evaluate preliminary efficacy of XL114 by estimating the ORR based on lymphoma-specific response criteria as assessed by the Investigator

    Time frame: 4-6 months

Secondary outcomes

  1. Safety of XL114, as evaluated by Adverse Events (AEs)

    To evaluate the safety of XL114 through the evaluation of incidence and severity of treatment emergent nonserious adverse events (AEs) and serious adverse events (SAEs)at each dose level and their relationship to study drug treatment.

    Time frame: 4-6 months

  2. Tolerability of XL114, as evaluated by Dose Intensity, Dose Modifications, and Study Discontinuation due to AEs

    To evaluate the tolerability of XL114 through the evaluation of dose intensity, dose modifications and study treatment discontinuation due to AEs related to XL114.

    Time frame: 4-6 months

  3. Dose-Escalation Stage: Time to Maximum Plasma Concentration (Tmax)

    To evaluate the Tmax of XL114.

    Time frame: 4-6 months

  4. Dose-Escalation Stage: Maximum Plasma Concentration (Cmax)

    To evaluate the Cmax of XL114.

    Time frame: 4-6 months

  5. Dose-Escalation Stage: Area Under the Plasma Concentration-Time Curve Over the Last 24-hour Dosing Interval (AUC 0-24)

    To evaluate the AUC 0-24 of XL114.

    Time frame: 4-6 months

  6. Dose-Escalation Stage: Terminal Half-Life

    To evaluate the terminal half-life of XL114.

    Time frame: 4-6 months

  7. Dose-Escalation Stage: Apparent Clearance (CL/F)

    To evaluate the CL/F of XL114.

    Time frame: 4-6 months

  8. Cohort-Expansion Stage: Antitumor Activity of XL114 (Objective Response Rate [ORR])

    To evaluate the antitumor activity of XL114 as measured by ORR based on lymphoma-specific response criteria as assessed by a Blinded Independent Radiology Committee (BIRC) for selected cohorts.

    Time frame: 4-6 months

  9. Cohort-Expansion Stage: Antitumor Activity of XL114 (Duration of Response [DOR])

    To evaluate the antitumor activity of XL114 as measured by DOR based on lymphoma-specific response criteria as assessed by the Investigator or by a Blinded Independent Radiology Committee (BIRC) for selected cohorts.

    Time frame: 4-6 months

  10. Cohort-Expansion Stage: Antitumor Activity of XL114 (Progression Free Survival [PFS])

    To evaluate the antitumor activity of XL114 as measured by PFS based on lymphoma-specific response criteria as assessed by the Investigator or by a Blinded Independent Radiology Committee (BIRC) for selected cohorts.

    Time frame: 4-6 months

  11. Cohort-Expansion Stage: Overall Survival (OS) of XL114

    To evaluate duration of overall survival (OS)

    Time frame: 4-6 months

08

Study locations

4 sites
  • Exelixis Clinical Site #3
    Tucson, Arizona 85719, United States
  • Exelixis Clinical Site #1
    Indianapolis, Indiana 46250, United States
  • Exelixis Clinical #4
    Pittsburgh, Pennsylvania 15224, United States
  • Exelixis Clinical Site #2
    Spokane, Washington 99208, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Nov 2022, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2021
First posted
Dec 3, 2021
StartActual
Apr 12, 2022
Primary completionActual
Nov 1, 2022
CompletionActual
Nov 1, 2022
Last update
Jul 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05144347
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Dec 3, 2021
Start date
Apr 12, 2022
Primary completion
Nov 1, 2022
Completion
Nov 1, 2022
Last update
Jul 11, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion